Impact of nonsteroidal anti-inflammatory drugs on efficacy of anti-PD-1 therapy for primary liver cancer.
10.12122/j.issn.1673-4254.2022.05.10
- Author:
Rui Ning LI
1
;
Chao Yi HUANG
1
;
Chang HONG
1
;
Jia Ren WANG
2
;
Qi Mei LI
2
;
Cheng Yi HU
1
;
Hao CUI
2
;
Zhong Yi DONG
3
;
Hong Bo ZHU
4
;
Li LIU
1
;
Lu Shan XIAO
1
Author Information
1. Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
2. Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
3. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
4. Department of Oncology, First Affiliated Hospital of University of South China, Hengyang 421001, China.
- Publication Type:Journal Article
- Keywords:
immunotherapy;
nonsteroidal anti-inflammatory drugs;
primary liver cancer
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use*;
Humans;
Immunotherapy/methods*;
Liver Neoplasms/drug therapy*;
Prospective Studies;
Retrospective Studies
- From:
Journal of Southern Medical University
2022;42(5):698-704
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on clinical outcomes of patients receiving anti-PD-1 immunotherapy for hepatocellular carcinoma.
METHODS:We conducted a retrospective study among 215 patients with primary liver cancer receiving immunotherapy between June, 2018 and October, 2020. The patients with balanced baseline characteristics were selected based on propensity matching scores, and among them 33 patients who used NSAIDs were matched at the ratio of 1∶3 with 78 patients who did not use NSAIDs. We compared the overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) between the two groups.
RESULTS:There was no significant difference in OS between the patients using NSAIDs (29.7%) and those who did not use NSAIDs (70.2%). Univariate and multivariate analyses did not show an a correlation of NSAIDs use with DCR (univariate analysis: OR=0.602, 95% CI: 0.299-1.213, P=0.156; multivariate analysis: OR=0.693, 95% CI: 0.330-1.458, P=0.334), PFS (univariate analysis: HR=1.230, 95% CI: 0.789-1.916, P=0.361; multivariate analysis: HR=1.151, 95% CI: 0.732-1.810, P=9.544), or OS (univariate analysis: HR=0.552, 95% CI: 0.208-1.463, P=0.232; multivariate analysis: HR=1.085, 95% CI: 0.685-1.717, P=0.729).
CONCLUSION:Our results show no favorable effect of NSAIDs on the efficacy of immunotherapy in patients with advanced primary liver cancer, but this finding still needs to be verified by future prospective studies of large cohorts.
